Table 1.
Target | Treatment | Stage of Development |
---|---|---|
IgE | Omalizumab | Marketed |
IL-5 | Mepolizumab Reslizumab |
Marketed |
IL-5R | Benralizumab | Phase III |
IL-4Rα (IL-4/IL-13) | Dupilumab Pitrakinra |
Phase III Phase II |
IL-13 | Lebrikizumab Tralokinumab |
Phase III Phase III |
IL-17 | Secukinumab Brodalumab |
Phase II Phase II |